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Abstract
AIM
To examine the relationship between elevated 
granulocyte-macrophage colony-stimulating factor (GM-
CSF) auto-antibodies (Ab) level and time to surgical 
recurrence after initial surgery for Crohn’s disease (CD). 
METHODS
We reviewed 412 charts from a clinical database at 
tertiary academic hospital. Patients included in the 
study had ileal or ileocolonic CD and surgical resection 
of small bowel or ileocecal region for management 
of disease. Serum samples were analyzed for serolog-
ical assays including GM-CSF cytokine, GM-CSF Ab, 
ASCA IgG and IgA, and genetic markers including 
SNPs rs2066843, rs2066844, rs2066845, rs2076756 
and rs2066847 in NOD2, rs2241880 in ATG16L1, 
and rs13361189 in IRGM. Cox proportional-hazards 
models were used to assess the predictors of surgical 
recurrence.
RESULTS
Ninety six percent of patients underwent initial ileocecal 
resection (ICR) or ileal resection (IR) and subsequently 
40% of patients required a second ICR/IR for CD. GM-
CSF Ab level was elevated at a median of 3.81 mcg/mL. 
Factors predicting faster time to a second surgery 
included elevated GM-CSF Ab [hazard ratio (HR) 3.52, 
95%CI: 1.45-8.53, P  = 0.005] and elevated GM-CSF 
cytokine (HR = 2.48, 95%CI: 1.31-4.70, P  = 0.005). 
Factors predicting longer duration between first and 
second surgery included use of Immunomodulators (HR 
= 0.49, 95%CI: 0.31-0.77, P  = 0.002), the interaction 
effect of low GM-CSF Ab levels and smoking (HR = 
0.60, 95%CI: 0.45-0.81, P  = 0.001) and the interaction 
effect of low GM-CSF cytokine levels and ATG16L1 (HR 
= 0.65, 95%CI: 0.49-0.88, P  = 0.006).
CONCLUSION
GM-CSF bioavailability plays a critical role in maintaining 
intestinal homeostasis. Decreased bioavailability 
coupled with the genetic risk markers and/or smoking 
results in aggressive CD behavior.
Key words: Inflammatory bowel disease; Granulocyte-
macrophage colony-stimulating factor antibody; Crohn’s 
disease; Surgery
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This retrospective study assesses the risk of 
surgery for management of ileal Crohn’s disease (CD) 
among patients with elevated granulocyte-macrophage 
colony-stimulating factor (GM-CSF) auto-antibodies 
(Ab). In this cohort, 396 subjects underwent initial 
ileocecal resection or ileal resection for management of 
disease. Subsequently 165 patients (41.7%) required 
a second ICR or IR. Factors predicting faster time to a 
second surgery were elevated GM-CSF Ab and elevated 
GM-CSF cytokine. Patients with low GM-CSF cytokine 
levels and the protective allele for ATG16L1 had longer 
intervals between a first and second surgery. To 
improve long term outcomes for patients with Ileal CD 
we need to optimize therapeutic options for patients 
with low GM-CSF bioavailability and genetic risk 
markers for ATG16L1.
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stimulating factor bioactivity accelerates surgical recurrence in 
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INTRODUCTION
The incidence and prevalence of Crohn’s disease (CD) 
continues to rise with the highest rates reported to be 
20.2 per 100000 person-years and 319 per 100000 
persons in North America[1]. This chronic inflammatory 
disease is characterized by a transmural inflammation 
and can involve any region of the gastrointestinal tract. 
The transmural involvement particularly involving the 
ileum, often leads to fibrosis, luminal narrowing, and 
fistulas. In one population based cohort study of adult 
patients with CD, the cumulative probability of major 
abdominal surgery was 38%, 48%, and 58% at 5, 10, 
and 20 years after diagnosis, respectively[2]. Endoscopic 
recurrence after the initial ileocolic resection for CD 
may occur in up to 73% of patients within the first year 
after surgery[3]. Further, disease recurrence resulting in 
a second surgery for CD may occur in 31% to 50% of 
patients within 10 years of the initial surgery[4,5].
A growing body of literature supports the use of 
serological and genetic markers to determine the 
prognosis for patients with increased risk for surgical 
recurrence. Granulocyte macrophage colony-stimulating 
factor (GM-CSF) is a cytokine that promotes myeloid cell 
development and maturation. In mice, deficiency of this 
important hematopoietic growth factor can contribute to 
mucosal inflammation and immunodeficiency[6,7]. Clinical 
trials of recombinant GM-CSF in CD have demonstr-
ated that it may benefit a subset of CD patients[8-10]. 
Conversely, as we and others have previously shown, 
neutralizing GM-CSF auto-antibodies (Ab) are associated 
with a reduced bioactivity of GM-CSF, impaired neutrophil 
bacterial killing, and increased rates of intestinal resection 
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for ileal CD[7,11,12]. 
In the present study, we examined the predictive 
capacity of GM-CSF Ab in surgical recurrence rates after 
initial ileocolic resection for ileal CD. We also evaluated 
other clinical, serologic and genetic prognostic factors 
that might define the subset of patients with shorter 
time to surgical recurrence.
MATERIALS AND METHODS
Study population
After obtaining institutional review board approval, 
patients with CD enrolled between January 2005 and 
October 2015 at Washington University Medical Center 
in St. Louis, MO, were identified from a prospectively 
maintained database of Inflammatory Bowel Disease 
patients at the Digestive Diseases Research Core 
Centers (DDRCC). A retrospective chart review was 
performed on all patients. Patients were excluded if the 
pathology report was not consistent with a diagnosis of 
CD. The retrospective chart review included surgical and 
gastroenterology office notes, surgical and endoscopic 
operative reports, hospital admission and discharge 
notes, pathology reports, and radiology studies. 
Study design
Patients included in the study had ileal or ileocolonic CD 
and surgical resection of small bowel or ileocecal region 
for management of disease. The diagnosis of CD was 
based on established clinical, radiological, endoscopic and 
histopathological criteria. The characteristics recorded at 
baseline included, age, gender, race/ethnicity, duration 
of disease, location and behavior according to the 
Montreal classification[13], smoking history, number and 
type of surgery, and exposure to IBD therapies. We also 
extracted available data for infection with Clostridium 
difficile (C. diff). 
DNA samples were obtained from peripheral whole 
blood samples collected at enrollment in the registry. 
Samples were genotyped using the Illumina Golden Gate 
custom Immunochip array. Genetic analysis focused on 
SNPs rs2066843, rs2066844, rs2066845, rs2076756 
and rs2066847 in NOD2, rs2241880 in ATG16L1, and 
rs13361189 in IRGM. These polymorphisms have a role 
in bacteria sensing and autophagy.
Serum concentrations of GM-CSF cytokine and Ab 
were quantified by enzyme-linked immunosorbent 
assay (ELISA) as previously described[7]. Based upon 
prior studies elevated serum GM-CSF Ab was defined 
as ≥ 1.6 mcg/mL.
ELISA for detection of anti-Saccharomyces cerevisiae 
antibodies
QUANTA Lite (INOVA Diagnostics, Inc., San Diego, 
CA, United States) ASCA IgG and IgA enzyme-
linked immunosorbent assays (ELISA) were used for 
determination of serum anti-Saccharomyces cerevisiae 
antibodies (ASCAs) levels as described by the man-
ufacturer’s instructions. Briefly, 100 microliters of 
patient’s serum at a dilution of 1:100 were added 
to 96-well polystyrene microwell plates adhered 
with partially purified and disrupted Saccharomyces 
cerevisiae antigen. Bound ASCAs were detected by 
incubation with horseradish peroxidase IgG or IgA 
conjugate (goat anti-human). The absorbance (optical 
density, OD) was read at 450 nm using a SpectraMax 
MiniMax Imaging Cytometer. On each plate a high and a 
low positive, as well as a negative control were included. 
ASCA reactivity was determined by the formula: sample 
OD⁄low positive OD × 25. The positive cut off values 
for both ASCA IgA and IgG as set by the manufacturer 
were 25 Units (U)/mL.
Statistical analysis
The statistical methods of this study were reviewed by 
Wei Zhu, PhD at Stony Brook University. Descriptive 
statistics of demographic variables were generated 
using Graph Pad Prism 5.04 for Windows, GraphPad 
Software, San Diego, CA, United States.
In order to detect risk factors associated with early 
surgical recurrence, a Cox proportional hazard model[14] 
was fitted with main effects and first-order interactions 
of clinical and genotype variables. A stepwise variable 
selection based on Bayesian information criteria (BIC) 
was performed to select the relevant subset of variables. 
Within the model, p value was adjusted as previously 
described by Li et al[15], with the cutoff at FDR < 0.05. 
Model fitting and selection were generated using R 3.1.1 
(http://cran.r-project.org).
RESULTS
Patient demographic and clinical characteristics
The study group included 412 adult patients with CD 
and a prior history of surgery for management of 
disease (Table 1). The mean age of CD patients at the 
time of this study was 49.9 ± 14.5 years. The mean 
disease duration was 22.5 ± 12.5 years. The majority 
of patients (50.26 %) were smokers.
The first surgical procedure for IBD management 
occurred at a median of 3 years post diagnosis. Most 
patients underwent intestinal resection with ileocolonic 
anastomosis. Ileocecal resection (ICR) was performed 
in 370⁄412 (90%) patients and ileal resection (IR) was 
performed in 26⁄412 patients (6.3%). The remaining 
3.2% of patients underwent other intestinal surgeries 
including total colectomy, ileostomy creation, upper 
small bowel surgery, partial colectomy, proctectomy, 
diverting colostomy, and enterofistula repair. Two 
hundred and fifty eight patients (62.62%) underwent 
the first surgery for management of CD prior to 
enrollment in the registry in 2005. Table 2 outlines the 
patient characteristics by Montreal Classification[13]. 
The mean age at diagnosis of CD patients was 27.8 ± 
11.7 years. Chart review revealed that 105 patients 
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ASCA IgG. Two hundred and eighty seven (70%) of 
patients were concordantly positive, 35 (8%) patients 
were concordantly negative, whereas 16 (4%) of 
patients were positive only for ASCA IgA and 28 (7%) 
only for ASCA IgG. The mean, median and range 
values of all four serological assays, ASCA IgA, IgG, 
GM-CSF cytokine and GM-CSF Ab are shown in Table 3.
Surgical recurrence after initial ICR or small bowel 
resection and associated risk or protective factors
A total of 224 patients (54.5%) required two or more 
IBD related surgical procedures. One hundred and 
twenty one patients (29.37%) underwent the second 
surgery for management of CD prior to enrollment in the 
registry in 2005. Chart review revealed that 187 patients 
(45.39%) had exposure to Immunomodulator therapy 
(Azathioprine, 6-mercaptopurine or Methotrexate) prior 
to a second surgery. In addition, 80 patients (29.13%) 
had exposure to Infliximab or Adalimumab prior to 
a second surgery. Time to the second surgery was 
significantly shorter in patients with structuring (B2) or 
penetrating (B3) disease behavior as shown in Figure 1.
Factors predicting a faster time to a second surgery 
were assessed by survival analysis using the Cox 
proportional hazard model to test for association with 
gender, disease phenotype, smoking status, serological 
assays, IBD polymorphisms and use of medications 
(Immunomodulators or anti-TNF) between the first 
and second surgery (Table 4). All serological assays 
(GM-CSF cytokine, GM-CSF Ab, ASCA IgA and ASCA 
IgG) were examined as continuous, log transformed 
variables while the remaining variables were included 
as categorical variables.
A total of 333 subjects were included in this analysis 
after removal of subjects who did not have ICR/IR and 
those with missing data. Patients with high GM-CSF 
cytokine or Ab levels had a significantly shorter time to 
a second surgery compared to those with low levels. 
Patients with exposure to immunomodulators between 
first and second surgery had significantly longer intervals 
to the second surgery.
When examining the interaction of GM-CSF with 
all the other variables patients with protective alleles 
for ATG16L1 and low GM-CSF cytokine levels had 
significantly longer intervals to the second surgery. 
Patients with the protective allele for ATG16L1 and low 
GM-CSF Ab levels also experienced a longer interval 
to the second surgery but this was not statistically 
significant. The other polymorphisms for the genes 
NOD2 and IRGM did not have significant correlation 
with time to the second surgery.
A positive smoking history did not correlate with 
a faster time to second surgery. The median GM-CSF 
Ab levels (Figure 2) was significantly lower in smokers 
when compared to non-smokers (p < 0.0001) and 
significantly lower when compared to ex-smokers (p 
< 0.01). In addition smokers who expressed low GM-
CSF Ab has significantly longer intervals to the second 
(25.48%) had exposure to Immunomodulator therapy 
(Azathioprine, 6-mercaptopurine or Methotrexate) prior 
to the first surgery. In addition, 80 patients (19.41%) 
had exposure to Infliximab or Adalimumab prior to the 
first surgery.
Prevalence of GM-CSF Ab and ASCA
Serum samples were drawn from 254 and 150 
patients before and after the first ICR/IR surgery for 
management of CD, respectively. Similarly serum 
samples were drawn from 98 and 67 patients before 
and after the second ICR/IR surgery, respectively. The 
serum GM-CSF Ab level was elevated at a median 
(interquartile range, IQR) of 3.81 (0.93-11.01) mcg/
mL and consistent with previous studies. There were 
273 (66.4%) CD cases with GM-CSF Ab level ≥ 1.6 
mcg/mL. When we applied the positive cut off values 
for both ASCA IgA and IgG as set by the manufacturer, 
25 U/mL, 313 ⁄ 412 (76%) of patients were positive 
for ASCA IgA and 334 ⁄ 412 (81%) were positive for 
Table 1  Demographic characteristics of the subjects
Patient characteristics (n  = 412) n  (%)
Gender, Female 242 (58.74)
Race, White 368 (89.3)
Age, mean ± SD 49.88 ± 14.49
Smoking 
   Current smoker 180 (43.69)
   Ex-smoker 27 (6.57)
   Never smoker 203 (49.27)
Surgery for CD1
   First Ileocolic resection 370 (89.80)
   First Ileal resection 26 (6.31)
   Second Ileocolic resection 152 (36.89)
   Second Ileal resection 13 (3.15)
Exposure to medication
   Immunomodulators pre-T1 105 (25.48)
   Anti-TNF agent pre-T1 80 (19.41)
   Immunomodulators pre-T2 187 (45.39)
   Anti-TNF agent pre-T2 120 (29.13)
13.2% of patients underwent other intestinal surgeries as noted in the 
results section of the text. CD: Crohn’s disease. 
Table 2  Phenotypes by Montreal classification
n  (%)
Age at diagnosis
   A1 (≤ 16) 56 (13.63)
   A2 (17-40) 296 (72.57)
   A3 (> 40) 60 (14.6)
Disease location
   L1 ileal 279 (67.71)
   L2 colonic 2 (0.485)
   L3 ileocolonic 131 (31.87)
   L4 upper GI disease 50 (12.17)
   p perianal disease 125 (30.41)
Disease behavior
   B1 non-stricturing, non-penetrating 35 (08.49)
   B2 stricturing 167 (40.63)
   B3 penetrating 197 (47.93)
Gathungu G et  al. GM-CSF bioactivity and repeat surgery in ileal CD
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DISCUSSION
In this cohort of 412 patients with ileal CD, 396 subjects 
underwent at least one ileocolic resection or ileal 
resection for management of their disease. Subsequently 
165 of them (41.7%) required a second ICR or IR. 
Within the cohort of 412 patients, 410 had isolated Ileal 
or ileocolonic disease, 2 patients had colonic disease but 
evolved to ileocolonic location by the conclusion of the 
study. Ileal disease location is associated with stricturing 
and penetrating disease behavior (B2/B3) and increased 
risk of surgery. In fact, we demonstrated a faster time 
to the second surgery in those with B2 and B3 disease 
behavior compared to non-stricturing, non-penetrating 
disease (B1). In addition, patients with structuring 
disease had significantly decreased rates of survival 
(Figure 1) to the second surgery (p = 0.0037). However, 
we sought to determine additional variables that are 
potentially modifiable in this large cohort of CD patients 
with aggressive ileal CD. 
We and others have reported previously, that 
elevated GM-CSF Ab is associated with increased 
rates of stricturing behavior and surgery in adult and 
pediatric CD[7,11,12]. Further, Däbritz et al[16], showed that 
longitudinal measurements of serum GM-CSF Ab levels 
in adult and pediatric patients with CD or ulcerative 
colitis reliably predicted disease recurrence 2 to 7 mo 
before a relapse as defined by clinical assessment using 
the Crohn’s or ulcerative colitis disease activity indices 
(CDAI, PCDAI, UCDAI, PUCAI) in Adults and Pediatric 
patients with CD or ulcerative colitis. In our cohort of 
ileal CD patients, the time to a second surgery was 
significantly accelerated in those with elevated GM-CSF 
Ab level even after accounting for all other variables in 
our analysis. This study confirms the prior association 
of elevated GM-CSF and aggressive CD and here we 
report the link between elevated GM-CSF Ab and a 
shorter time to surgical recurrence.  
GM-CSF cytokine has a central role in intestinal 
homeostasis by enhancing innate immune responses to 
microbial pathogens[17]. Within the gastrointestinal tract, 
expression of GM-CSF cytokine is found on Paneth cells 
of the intestine and the GM-CSF receptor beta chain is 
present along epithelial cells of the small intestine[18]. 
While the underlying pathogenesis that drives over-
expression of GM-CSF Ab is not fully defined, in vitro 
studies demonstrate a neutralizing effect on GM-CSF 
cytokine activity by reducing the bioactivity of free 
GM-CSF[7]. GM-CSF autoantibodies are produced by 
lamina propria mononuclear cells isolated from resection 
specimen from patients with stricturing CD[19]. In addition 
patients with elevated GM-CSF have reduced neutrophil 
bacterial killing[19]. The addition of GM-CSF cytokine 
increases neutrophil bacterial killing in CD only on 
washed neutrophils in which GM-CSF antibodies are 
depleted[19]. We examined GM-CSF cytokine level in this 
Table 3  Values for serological assays
Serological assays Mean ± SD Median (IQRs) Range
GM-CSF cytokine, pg/mL 3.18 ± 8.61 1.28 (0.43-3.05) 0.0052-136.5
GM-CSF Ab, mcg/mL 10.64 ± 19.76 3.81 (0.93-11.01) 0.08-241.2
ASCA IgA, U/mL 95.21 ± 77.38 67.51 (27.86-174.4) 1.92-242.8
ASCA IgG, U/mL 69.79 ± 41.09 66.86 (31.76-104.2) 3.17-158.1




P  = 0.0037







Figure 1  Comparison of survival Kaplan-Meier curves of patients according 
to disease behavior. Log-rank test, P = 0.0037. CD: Crohn’s disease.























P  < 0.0001 P  < 0.01
Figure 2  Serum granulocyte-macrophage colony-stimulating factor auto-
antibodies levels in patients with Crohn’s disease stratified by smoking 
status. The log10 transformation of serum GM-CSF Ab (in micrograms per 
milliliter) is shown. The middle line represents the median, and the lower 
edge and the upper edge of the box represent the 25% and 75% quartiles, 
respectively. The bottom and top lines represent the minimum and maximum 
values, respectively. There were 201 non-smokers, 180 smokers and 27 ex-
smokers with CD. Kruskal-Wallis test with Dunn’s post-test revealed significant 
differences between non-smokers and smokers and between smokers and ex-
smokers. GM-CSF Ab: Granulocyte-macrophage colony-stimulating factor auto-
antibodies; CD: Crohn’s disease. 
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study and found that patients with elevated levels had 
significantly shorter intervals to the second surgery. We 
also evaluated the interaction between GM-CSF cytokine 
and its neutralizing antibody and found no interaction 
effect. In healthy individuals, GM-CSF in the circulation 
is tightly regulated at low or even undetectable levels 
but can rise to high levels in response to immune stimuli 
such as lipopolysaccharide. Chronic overexpression 
leads to pathological changes that can result in severe 
damage to affected organs[20]. This may be explained by 
the pleiotropic effects that result from GM-CSF cytokine 
function[21].  
We confirmed that use of imunomodulators is asso-
ciated with a longer duration between the first and 
second surgical resection for CD. This finding first 
reported by Unkart et al[22] highlights the importance of 
step up therapy in a subset of patients with aggressive 
CD behavior. It is reported that early use of TNF anta-
gonists is associated with reduced risk of developing 
strictures in adults[23] and in children early monotherapy 
with TNF antagonists results in better overall clinical and 
growth outcomes at 1 year[24]. In this study, 70.2% of 
patients exposed to TNF antagonists after the initial ICR/
IR did not require a second surgery. In addition, only 
27.8% of the 165 patients that required a second ICR/
IR had exposure to TNF antagonists prior to the second 
surgery. Nonetheless we did not find that exposure to 
TNF antagonists was associated with a longer duration 
between the first and second surgery. It is worthwhile 
mentioning that the earliest use of TNF antagonists for 
this cohort was the year 1994 but 31 subjects (18.8%) 
required 2 or more ICR/IR surgical events prior to this 
year. In addition 144 subjects (87.2%) who required a 
second surgery had long standing disease of 3 or more 
years prior to the second surgery.    
In this study a large subset of patients were current 
or ex-smokers (50.1%) and practically all subjects 
except one had ileal disease location. In a prior study 
we found that smokers with Ileal CD had lower GM-
CSF Ab levels[12]. Similarly, in the present cohort the 
median GM-CSF Ab level was 2.5 in smokers and 5.4 
in non-smokers (Figure 2). This resulted in a complex 
interaction effect of smoking such that smokers who 
expressed low GM-CSF Ab level had a longer interval 
Table 4  Risk factors at or after the initial Crohn’s disease surgery associated with time to the second Crohn’s disease surgery
Main effects HR 95%CI P  value FDR
Immunomodulators1 0.486 0.306-0.773 0.002 0.026
GM-CSF Ab level 3.493 1.430-8.538 0.005 0.030
GM-CSF cytokine level 2.489 1.292-4.796 0.005 0.030
B2 disease behavior2 1.415 0.517-3.874 0.491 0.624
B3 disease behavior3 0.415 0.146-1.176 0.091 0.145
Smoking4 1.286 0.277-5.981 0.743 0.800
ASCA IgG, U/mL 1.318 0.799-2.174 0.270 0.378
Age at diagnosis 0.983 0.963-1.003 0.094 0.145
Clostridium difficile infection 0.035 0.001-1.092 0.051 0.113
antiTNF-α5 1.272 0.662-2.447 0.461 0.615
ATG16L1 polymorphism 1.793 0.982-3.273 0.052 0.113
IRGM polymorphism 0.092 0.004-2.262 0.136 0.201
ASCA IgA, U/mL 0.976 0.755-1.262 0.852 0.852
NOD2 polymorphisms 1.123 0.741-1.702 0.577 0.673
Interactions
   GM-CSF Ab level and smoking 0.612 0.454-0.825 0.001 0.026
   GM-CSF cytokine level and ATG16L1 0.652 0.480-0.885 0.005 0.030
   GM-CSF Ab  level and ASCA IgG, U/mL 0.808 0.674-0.968 0.018 0.081
   GM-CSF Ab level and ATG16L1 0.719 0.538-0.962 0.023 0.081
   B2 disease behavior and Clostridium difficile 21.57 1.456-319.271 0.023 0.081
   B2 disease behavior and smoking 1.601 0.318-8.059 0.560 0.673
   B3 disease behavior and smoking 5.117 0.966-27.141 0.050 0.113
   GM-CSF Ab level and Clostridium difficile 2.865 1.065-7.715 0.033 0.104
   GM-CSF cytokine level and Clostridium difficile 0.902 0.325-2.501 0.840 0.852
   Smoking and IRGM 0.406 0.145-1.134 0.079 0.145
   ASCA IgG, U/mL and IRGM 1.867 0.908-3.835 0.083 0.145
   GMCSF cytokine level and antiTNF-α 0.765 0.562-1.041 0.082 0.145
   GM-CSF Ab level and antiTNF-α 0.941 0.703-1.260 0.676 0.757
   GM-CSF cytokine level and ASCA IgA, U/mL 0.865 0.750-0.997 0.041 0.113
1Use of Immunomodulators between first and second CD surgery including: Azathioprine, 6-Mercaptopurine, Methotrexate; 2Stricturing behavior (B2) 
compared to Inflammatory (B1) disease behavior; 3Penetrating behavior (B3) compared to Inflammatory (B1) disease behavior; 4Active smoker before 
the first CD surgery; 5Use of Anti-tumor Necrosis Factor-alpha therapy between first and second CD surgery including: Infliximab, Adalimumab. Cox 
proportional hazard model; A Cox proportional hazard model was fitted with main effects and first-order interactions of clinical and genotype variables. A 
stepwise variable selection was performed to select the relevant subset of variables. Within the model, P value was adjusted with the cutoff at FDR < 0.05. 
Model fitting and selection were generated using R 3.1.1 (http://cran.r-project.org). Table 4 displays the P-values for all fitted terms in the final model. GM-
CSF Ab: Granulocyte-macrophage colony-stimulating factor auto-antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies; CD: Crohn’s disease. 
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between the first and second surgery. 
A limitation of the study was the retrospective nature 
of the clinical data collection. In addition we were not 
able to clearly delineate precise duration of exposure 
to immunomodulators or biologics, the response and 
tolerance of these medications. The serum collection 
was cross sectional and so future studies should exa-
mine serial measurements that correlate with time of 
diagnosis and surgical events.
The strengths of our study are that we were able 
to distinguish between modifiable and non-modifiable 
factors that impact disease behavior in CD. Modifiable 
factors like preventing exposure to smoking and early 
use of immunomodulators and TNF antagonists are 
well recognized but it is important to highlight their role 
in prevention of aggressive disease behavior. The non-
modifiable factors like GM-CSF cytokine bioavailability 
and carriage of risk alleles for ATG16 L1 can be used 
to profile patients that may benefit from top-down 
therapy or alternatively newer more targeted therapy.
ARTICLE HIGHLIGHTS
Research background
Crohn’s disease (CD) is a chronic inflammatory disease is characterized by a 
transmural inflammation that targets any region of the gastrointestinal tract. The 
transmural involvement particularly involving the ileum, often leads to fibrosis, 
luminal narrowing, and fistulas. In one population based cohort study of adult 
patients with CD, the cumulative probability of major abdominal surgery was 
38% to 58% within 5 to 20 years after diagnosis. Further, disease recurrence 
resulting in a second surgery for management of CD may occur in 31% to 
50% of patients within 10 years of the initial surgery. There remains a need for 
serological and genetic markers that can reliably identify patients with increased 
risk for surgical recurrence.
Research motivation
Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine 
that promotes myeloid cell development and maturation. Deficiency of this 
important hematopoietic growth factor can contribute to mucosal inflammation 
and immunodeficiency. We and others have previously shown, neutralizing GM-
CSF auto-antibodies (Ab) are associated with a reduced bioactivity of GM-CSF, 
impaired neutrophil bacterial killing, and increased rates of intestinal resection 
for ileal CD. In the present study, we examined the predictive capacity of GM-
CSF Ab in surgical recurrence rates after initial ileocolic resection for ileal CD. 
We also evaluated other clinical, serologic and genetic prognostic factors that 
might define the subset of patients with shorter time to surgical recurrence.
Research objectives
The development of biomarkers for diagnosis and prognosis of CD is evolving 
and serological assays like ASCA, ANCA, Anti-glycan antibodies and GM-CSF 
Ab are important discoveries. Some assays are reliable predictors for diagnosis 
and for staging severity. Here we demonstrate that GM-CSF Ab is a reliable 
biomarker for characterizing severity and reliably predicts patients at greater 
risk for aggressive disease behavior and the need for surgery.
Research methods
We reviewed 412 patients which included in the study had ileal or ileocolonic 
CD and surgical resection of small bowel or ileocecal region for management of 
disease from a clinical database at tertiary academic hospital. Serum samples 
were analyzed for serological assays, which included GM-CSF cytokine, GM-
CSF Ab, ASCA IgG and IgA, and genetic markers included SNPs rs2066843, 
rs2066844, rs2066845, rs2076756 and rs2066847 in NOD2, rs2241880 in 
ATG16L1, and rs13361189 in IRGM. The predictors of surgical recurrence were 
assessed by the Cox proportional-hazards models.
Research results
Of 96% patients underwent initial Ileocecal resection (ICR) or Ileal resection (IR) 
and subsequently 40% of patients required a second ICR/IR for CD. GM-CSF 
Ab level was elevated at a median of 3.81 mcg/mL. Factors predicting faster 
time to a second surgery included elevated GM-CSF Ab and elevated GM-CSF 
cytokine. Factors predicting longer duration between first and second surgery 
included use of Immunomodulators, the interaction effect of low GM-CSF Ab 
levels and smoking, and the interaction effect of low GM-CSF cytokine levels 
and ATG16L1.
Research conclusions
In this study patients with elevated GM-CSF Ab had shorter intervals between 
the first and second surgery for management of CD. This is the first study to 
describe this. Therefore routine surveillance of this serological assay may 
facilitate the identification of patients at risk for disease complications and allow 
clinicians to optimize medical therapy. 
Research perspectives
Elevated GM-CSF Ab is a reliable assay for defining patients who are at a 
greater risk for surgery. A clinical assay is needed.
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